Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease.
Wang CY, Kuo BS, Lee YH, Ho YH, Pan YH, Yang YT, Chang HC, Fu LF, Peng WJ. Wang CY, et al. iScience. 2024 Jan 17;27(2):108887. doi: 10.1016/j.isci.2024.108887. eCollection 2024 Feb 16. iScience. 2024. PMID: 38318376 Free PMC article.
UB-612 vaccination safely induces potent, broad, and long-lasting immunity against SARS-CoV-2. ...The UB-612 multitope vaccine may serve as an effective primer and booster for those at risk of SARS-CoV-2 infection....
UB-612 vaccination safely induces potent, broad, and long-lasting immunity against SARS-CoV-2. ...The UB-612 mul …
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, Wang L, Johnson M, Hunt A, Hu MM, Monath TP, Rumyantsev A, Goldblatt D. Guirakhoo F, et al. J Infect Dis. 2022 Oct 17;226(8):1401-1406. doi: 10.1093/infdis/jiac241. J Infect Dis. 2022. PMID: 35723969 Free PMC article.
Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a pote …
Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimate …
RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.
Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C, Thibodeaux B, Sahni J, Hellerstein M, Kuzmina NA, Bukreyev A, Dodart JC, Rumyantsev A. Wang S, et al. Vaccines (Basel). 2023 Dec 29;12(1):40. doi: 10.3390/vaccines12010040. Vaccines (Basel). 2023. PMID: 38250853 Free PMC article.
In cynomolgus macaques, UB-612 induced potent serum-neutralizing, RBD-specific IgG binding, ACE2 binding-inhibition antibodies, and antibodies with Fc-mediated effector functions in ADMP and ADNKA assays. ...The level of mucosal or serum ADMP and ADNKA antibodies wa …
In cynomolgus macaques, UB-612 induced potent serum-neutralizing, RBD-specific IgG binding, ACE2 binding-inhibition antibodies …
How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022.
Lai CC, Lee PI, Hsueh PR. Lai CC, et al. J Microbiol Immunol Infect. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6. J Microbiol Immunol Infect. 2023. PMID: 37061349 Free PMC article. Review.
In the meanwhile, two COVID-19 vaccines, namely MVC-COV1901 and UB-612, have been developed under the support of government. Furthermore, MVC-COV1901 was taken into clinical practice after received emergency use approval. ...
In the meanwhile, two COVID-19 vaccines, namely MVC-COV1901 and UB-612, have been developed under the support of government. F …
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.
Wang CY, Peng WJ, Kuo BS, Ho YH, Wang MS, Yang YT, Chang PY, Shen YH, Hwang KP. Wang CY, et al. PLoS Pathog. 2023 Apr 20;19(4):e1010870. doi: 10.1371/journal.ppat.1010870. eCollection 2023 Apr. PLoS Pathog. 2023. PMID: 37079651 Free PMC article.
To a subpopulation (N = 1,478) of infection-free participants (aged 18-85 years) involved in a two-dose Phase-2 trial, a UB-612 booster (third dose) was administered 6-8 months after the second dose. ...This UB-612 booster vaccination is safe and well …
To a subpopulation (N = 1,478) of infection-free participants (aged 18-85 years) involved in a two-dose Phase-2 trial, a UB-612 …
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.
Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, Huang JH, Liu H, Ho YH, Lin F, Ding S, Liu Z, Wu HT, Huang CT, Lee YJ, Liu MC, Yang YC, Lu PL, Tsai HC, Lee CH, Shi ZY, Liu CE, Liao CH, Chang FY, Chen HC, Wang FD, Hou KL, Cheng J, Wang MS, Yang YT, Chiu HC, Jiang MH, Shih HY, Shen HY, Chang PY, Lan YR, Chen CT, Lin YL, Liang JJ, Liao CC, Chou YC, Morris MK, Hanson CV, Guirakhoo F, Hellerstein M, Yu HJ, King CC, Kemp T, Heppner DG, Monath TP. Wang CY, et al. J Clin Invest. 2022 May 16;132(10):e157707. doi: 10.1172/JCI157707. J Clin Invest. 2022. PMID: 35316221 Free PMC article. Clinical Trial.
BackgroundThe Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612, a multitope subunit vaccine containing S1-RBD-sFc protein and rationally designed promi …
BackgroundThe Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We repo …
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
Wang S, Wang CY, Kuo HK, Peng WJ, Huang JH, Kuo BS, Lin F, Liu YJ, Liu Z, Wu HT, Ding S, Hou KL, Cheng J, Yang YT, Jiang MH, Wang MS, Chen T, Xia WG, Lin E, Hung CH, Chen HJ, Shih Z, Lin YL, Ryan V, Hu MM, Heppner DG, Malherbe DC, Periasamy S, Kuzmina N, Subramani C, Hellerstein M, Monath TP, Rumyantsev A, Bukreyev A, Guirakhoo F. Wang S, et al. Emerg Microbes Infect. 2022 Dec;11(1):2724-2734. doi: 10.1080/22221751.2022.2140608. Emerg Microbes Infect. 2022. PMID: 36287714 Free PMC article.
The immunogenicity and protective immunity induced by UB-612 vaccine were evaluated in four animal models: Sprague-Dawley rats, AAV-hACE2 transduced BALB/c mice, rhesus and cynomolgus macaques. UB-612 vaccine induced high levels of neutralizing antibod …
The immunogenicity and protective immunity induced by UB-612 vaccine were evaluated in four animal models: Sprague-Dawley rats …